Editorial Board

Meet the OBR Editorial Board

Editor's Note: At OBR we have created an editorial board of renown thought leaders in different cancer disease areas. The role of our editorial board is to provide valuable insights through editorial commentary accompanying our daily news. We call it virtual access. By providing our insights into the daily news, you will have access into how these thought leading oncologists interpret the oncology news and events we carry in OBR daily. We hope that our editorial boards's insights will bring great value to the oncology community.

View all Editorial Board Member Commentary

Browse Editors by Section

Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center

Comments

U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer

quotes This label approval of palbociclib for male breast cancer is an example of creativity to address sub… quotes

Meet the OBR Editorial Board

Browse Editors by Section

Debu Tripathy, MD

Comments

U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer

Howard S. Hochster, MD

Comments

FDA Warns Companies To Stop Making ‘Unsubstantiated’ Claims About CBD Curing Cancer And Alzheimer’s

Richard Goldberg, MD

Comments

Study Examines 'Watch-And-Wait' Approach for People with Rectal Cancer

Ted Okon

Comments

PBM Middlemen Continue to Dodge Responsibility for Patient Suffering and Rising Drug Prices

William McGivney, PhD

Comments

AMA Says Prior Authorizations Increasing, Interfering With Care Continuity

Tomasz M. Beer, MD, FACP

Comments

ADXS-PSA in Combination with KEYTRUDA® Prolonged Survival in Metastatic Castration-Resistant Prostate Cancer

H. Jack West, MD

Comments

FDA Approves Expanded Monotherapy Label for Merck’s KEYTRUDA® (pembrolizumab)

Winston Wong, PharmD

Comments

Dana-Farber Cancer Institute Analyzes Clinical Pathway Use to Reduce Unwarranted Variation

Michael G. King Jr.

Comments

U.S. Food and Drug Administration Approves POMALYST® (pomalidomide) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Jennifer Levin Carter, MD, MPH

Robert A. Figlin, MD., FACP

Comments

CT Scans Can Reduce Lung Cancer Deaths, Study Finds

Dean Gesme, MD

Comments

They’re The Next New Thing In Cancer Immunotherapy, But Will Bispecifics Help More Patients Than CAR-Ts?

Jeff Patton, M.D.

Comments

First Opinion: Physicians Aren’t ‘Burning Out.’ They’re Suffering From Moral Injury

Thomas Marsland, MD

Comments

Doctors Without Appointments

William Harwin MD

Comments

Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas

Howard Sandler, MD, MS, FASTRO

Comments

Researchers Assess the Accuracy of 68Ga-PSMA-11 PET in Localizing Prostate Cancer